A5101584465- Multiple Myeloma Research and Treatments
- Frailty in Older Adults
- Chronic Lymphocytic Leukemia Research
- Health Systems, Economic Evaluations, Quality of Life
- CAR-T cell therapy research
- Nutrition and Health in Aging
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Amyloidosis: Diagnosis, Treatment, Outcomes
- COVID-19 and healthcare impacts
- Platelet Disorders and Treatments
- Acute Myeloid Leukemia Research
- Economic and Financial Impacts of Cancer
- Venous Thromboembolism Diagnosis and Management
- Cancer survivorship and care
- Global Cancer Incidence and Screening
- Protein Degradation and Inhibitors
- Atrial Fibrillation Management and Outcomes
- Telemedicine and Telehealth Implementation
- Dermatological and COVID-19 studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neural Networks and Applications
- Advanced Breast Cancer Therapies
- Drug-Induced Hepatotoxicity and Protection
- Immunodeficiency and Autoimmune Disorders
Hospital Universitario Fundación Jiménez Díaz
2012-2024
Islamic Azad University, Tehran
2024
Masih Daneshvari Hospital
2021
Shahid Beheshti University of Medical Sciences
2021
Clínica Rementería
2008
Hospital Universitario Fundación Alcorcón
2008
Abstract Purpose A study analyzing the application of a protocol comprehensive geriatric assessment (CGA) in older patients with lymphoma was carried out to allow frailty-based patient classification and individualized treatment. Methods Lymphoma than 70 years referred Geriatric Clinic at tertiary hospital between May 2016 March 2021 were included. The included comorbidity, polypharmacy, nutritional, functional, mental status, syndromes, life expectancy. CGA enabled into four groups (Type I...
Background: Talquetamab (tal; JNJ-64407564) is a first-in-class, bispecific IgG4 antibody that binds both to G protein-coupled receptor family C group 5 member D (GPRC5D), highly expressed on malignant plasma cells but with limited expression in healthy tissue, and CD3 mediate T-cell–activated lysis of GPRC5D+ multiple myeloma (MM) cells. Daratumumab (dara) an anti-CD38 mAb direct on-tumor immunomodulatory actions. Initial clinical results from the phase 1b multicohort TRIMM-2 study...
Belantamab mafodotin (BM) is a new anti-BCMA antibody-drug conjugate, recently approved for triple-class relapsed and refractory multiple myeloma (RRMM). We assessed real-world outcomes with BM in patients under the Spanish Expanded Access Program (EAP).
We retrospectively evaluated 2879 hospitalized COVID-19 patients from four hospitals to evaluate the ability of demographic data, medical history, and on-admission laboratory parameters predict in-hospital mortality. Association previously published risk factors (age, gender, arterial hypertension, diabetes mellitus, smoking habit, obesity, renal failure, cardiovascular/ pulmonary diseases, serum ferritin, lymphocyte count, APTT, PT, fibrinogen, D-dimer, platelet count) with death was tested...
Abstract Background There is evidence suggesting that most thromboembolic complications could be prevented with adequate pharmacological anticoagulation. We estimated the direct health care costs of anticoagulant treatment oral vitamin K antagonists in patients diagnosed non-valvular atrial fibrillation. Methods This observational study examined clinical records fibrillation who received antagonists. Data from were used study: international normalized ratio, number monitoring visits, type...
On March 14, 2020, a state of alarm was declared in Spain due to the spread SARS-CoV-2. Beyond this date, COVID-19 country changed practice oncologic care.Since recurrent hospital visits were potential risk factor for contagion, aim prospective observational study analyze consequences pandemic health care patients with lymphoma.All data obtained from electronic medical record. Variables such as age, sex, reason visit, use patient portal, changes management, enrollment clinical trials, and...
Waldenström macroglobulinemia (WM) is a slowly progressive hematologic malignancy that usually responds rapidly to treatment. Being lymphoplasmacytoid neoplasm, it associated with monoclonal IgM component, which may be multiple manifestations and symptoms. We report the case of 77-year-old woman diagnosed WM following development severe sudden pancytopenia cold agglutinin syndrome. In order treat underlying hemolysis, treatment rituximab, corticosteroids cyclophosphamide was started. Despite...
Diver’s disease is a complication that the human body suffers from after being in high-pressure space and then quickly entering low-pressure space. These pressures are very harmful for tissues of body, especially brain. Decompression sickness occurs when nitrogen bubbles up bloodstream, caused by staying underwater too long or surfacing quickly. symptoms usually appear with delay diving. By processing electroencephalography, information about neurophysiological disorders can be extracted...
G protein-coupled receptor family C group 5 member D (GPRC5D) has limited expression in healthy human tissue but is highly expressed malignant plasma cells, making it a promising target for immunotherapy approaches MM. Talquetamab (JNJ-64407564) first-in-class bispecific antibody that binds to both GPRC5D and CD3 receptors redirect T cells kill MM cells. Updated new results of talquetamab at the recommended phase 2 doses (RP2Ds) are reported (NCT03399799). Eligible patients had RRMM or were...
Heart failure (HF) with preserved ejection fraction (HFpEF) and monoclonal gammopathy of uncertain significance (MGUS) are two entities that share pathophysiological mechanisms. The aim herein, was to assess the prevalence MGUS in patients HFpEF no left ventricular (LV) hypertrophy, as well its association a pre-specified clinical endpoint at 12 months.The present study prospectively enrolled 69 admitted HF, ≥ 50%, LV wall thickness < mm. All were screened for MGUS. Clinical events...
Patients with MM continue to relapse on current therapies, stressing the need for new immunotherapy targets. GPRC5D is an orphan receptor that expressed malignant plasma cells in MM. Talquetamab (JNJ-64407564) a bispecific IgG4 antibody binds and CD3, redirecting T cell killing cells. Updated phase 1 results of talquetamab at recommended 2 dose (RP2D) patients RRMM are presented. Eligible had or were intolerant standard therapies. received intravenously (IV; range 0.5–180 μg/kg)...